TCGA-22-1017-01A-01R-0692-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- INTERFERON_GAMMA_RESPONSE+0.370
- MYC_TARGETS_V1+0.370
- INTERFERON_ALPHA_RESPONSE+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.350
- COMPLEMENT+0.310
- PROTEIN_SECRETION+0.310
- IL6_JAK_STAT3_SIGNALING+0.280
- ALLOGRAFT_REJECTION+0.270
- GLYCOLYSIS+0.270
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- WNT_BETA_CATENIN_SIGNALING-0.270
- MYOGENESIS-0.150
- NOTCH_SIGNALING-0.110
- UV_RESPONSE_DN-0.110
- BILE_ACID_METABOLISM-0.090
- APICAL_JUNCTION-0.070
- KRAS_SIGNALING_DN-0.060
- APICAL_SURFACE-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5903550 | — | cohortA4 | 0.844 |
| 2 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.833 |
| 3 | SRR6013499 | — | cohortA1 | 0.823 |
| 4 | SRR6013500 | — | cohortA1 | 0.820 |
| 5 | be22f883.ee5e.4632.93d1.661ddc53608e | — | cohortA4 | 0.808 |
| 6 | DRR168600 | — | — | 0.807 |
| 7 | SRR6013490 | — | cohortA4 | 0.806 |
| 8 | DRR168585 | — | — | 0.799 |
| 9 | TCGA-05-4395-01A-01R-1206-07 | — | cohortA4 | 0.799 |
| 10 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |